Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
North America Proton Therapy Market By Type of System, By Application, By End-User and Country
North America Proton Therapy Market By Type of System, By Application, By End-User and Country
North America Proton Therapy Market size was valued at US$ x million in 2023 and is expected to grow at a significant CAGR of 12.6% from 2024 to 2030. As protons have a positive charge, they can kill cancer cells at high energies. A non-invasive method of treating cancer, proton therapy uses radiation from protons. This kind of radiation treatment uses external beams to gently inject radiation from outside the body via the skin.
Proton therapy is the most common form of radiotherapy used for rhabdomyosarcoma, medulloblastoma, ependymoma, and Ewing sarcoma. Proton therapy, particularly pencil beam scanning, is expected to lower second cancer risks due to more targeted delivery of the radiation to the site of the first primary cancer. Globally and in the United States, cancer significantly influences society and drives the market growth of the market. The statistics on cancer depict the disease's impact on society over time. For instance, according to the data updated by the American Cancer Society in January 2023, in the US, breast cancer is the most prevalent cancer to affect women. It represents one in three, or 30%, of all newly diagnosed female cancers in the nation each year. Over 75% of National Comprehensive Cancer Network centres provide the option of proton therapy for their patients or plan to incorporate proton therapy into their cancer programs which can be seen as an opportunity in North America's proton therapy market.
However, the lack of adequate healthcare infrastructure and high installation costs decline the market growth. For instance, due to a lack of proton therapy technology and devices, 64% of patients experienced an average wait time of more than 5 days for PT treatment authorization in 2022, an increase of 48% from 2021. In addition, 22% of patients in 2022 had an average wait time of more than 11 days, up from 14.7% in 2021. Proton therapy currently represents less than 1% of all radiation oncology treatments by modality, and approximately 70% of the U.S. population lives more than 100 miles from a treatment centre.
Study Period
2024– 2030Base Year
2023CAGR
12.6%Largest Market
North AmericaFastest Growing Market
N/A
Growing number of radiotherapy centres in North America coupled with the increase in the prevalence of the cancer cases expected to booster the market growth of North America proton therapy market over the forecast period. Additionally, North America proton therapy market is mainly driven by an increase in the adaptation radiation therapies in the treatment of cancer. For instance, according to the most recent data, there are 43 proton treatment facilities with 113 treatment rooms open in the United States.
Between 2013 and 2022, there was a 176% rise in patients using proton treatment. A rise of almost 25% has been observed in the number of patients undergoing re-irradiation among those undergoing proton therapy, rising from 1,824 in 2021 to 2,293 in 2022. In recent years, single-room centers have become the majority of proton therapy centers in the United States.
Major companies such as IBA also launch new items, which helps to expand the market. Reputable for its creative ideas and noteworthy contributions to the treatment of cancer, IBA is a frontrunner in the fields of radiation and proton therapy. A unique and versatile proton treatment device designed for clinical excellence is IBA's Proteus® technology.
Geographically North America proton therapy market is segmented into United States (U.S.) and Canada. U.S. proton therapy market is expected to grow at significant rates owing to the presence of global market players and growing adaptation of the proton therapy for the treatment of cancers. Cancer has a major impact on society in the United States in North America. The very common cancers are pancreatic cancer, breast cancer, colon and rectum cancer, prostate cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, lung and bronchus cancer, leukaemia, thyroid cancer, and liver cancer. Each year in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 died from it, making it the second leading cause of death.
Canada proton therapy market is expected to have a notable growth rate over the forecast period due to the recent product approvals and growing adoption rates of the proton therapy. For instance, In February 2015, Mevion 250 proton system received medical device license from Health Canada, and it is first of its kind to receive the license from Health Canada. The number of patients receiving proton therapy increased 176% from 2013 to 2022.
Geographically North America proton therapy market is segmented into United States (U.S.) and Canada. U.S. proton therapy market is expected to grow at significant rates owing to the presence of global market players and growing adaptation of the proton therapy for the treatment of cancers. Cancer has a major impact on society in the United States in North America. The very common cancers are pancreatic cancer, breast cancer, colon and rectum cancer, prostate cancer, bladder cancer, kidney and renal pelvis cancer, endometrial cancer, lung and bronchus cancer, leukaemia, thyroid cancer, and liver cancer. Each year in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 died from it, making it the second leading cause of death.
Canada proton therapy market is expected to have a notable growth rate over the forecast period due to the recent product approvals and growing adoption rates of the proton therapy. For instance, In February 2015, Mevion 250 proton system received medical device license from Health Canada, and it is first of its kind to receive the license from Health Canada. The number of patients receiving proton therapy increased 176% from 2013 to 2022.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024– 2030 |
|
Market CAGR |
12.6% |
|
By Type |
|
|
By Application |
|
|
By End User |
|
Download Free Sample Report
The North America Proton Therapy Market is expected to grow at a significant CAGR of 12.6% from 2024 to 2030
In the United States, there are 43 active proton treatment facilities with 113 treatment rooms.
US is leading the Proton therapy market in North America. Since, each year in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 died from it, making it the second leading cause of death.? US is leading the Proton therapy market in North America. Since, each year in the United States, more than 1.6 million people are diagnosed with cancer, and almost 600,000 died from it, making it the second leading cause of death.
Lack of adequate healthcare infrastructure declines the market growth. For instance, 64% percent of patients experienced an average wait time of more than 5 days for PT treatment authorization in 2022, an increase of 48% from 2021. In addition, 22% of patients in 2022 had an average wait time of more than 11 days, up from 14.7% in 2021. Proton therapy currently represents less than 1% of all radiation oncology treatments by modality, and approximately 70% of the U.S. population lives more than 100 miles from a treatment centre.
Cancer has a huge impact on society both nationally and globally, which propels the proton therapy market's expansion. Cancer statistics show how the disease has affected society over time. For instance, the American Cancer Society's January 2023 data update indicates that breast cancer is the most common cancer among women in the US. 30%, or one in three, of all newly diagnosed female cancers in the country are represented by it annually.
| 1. Executive Summary |
| 2. North America Proton Therapy Market Introduction |
| 2.1. North America Proton Therapy Market - Taxonomy |
| 2.2. North America Proton Therapy Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Application |
| 2.2.3.End Users |
| 2.2.4.Country |
| 3. North America Proton Therapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. North America Proton Therapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. North America Proton Therapy Market By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Single Room System |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Multi-Room System |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. North America Proton Therapy Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Paediatric Cancer |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Head & Neck Cancer |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Prostate Cancer |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Lung Cancer |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Gastro-Intestinal Cancer |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Brain Cancer |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7. North America Proton Therapy Market By End Users, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Radiotherapy Centres |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. North America Proton Therapy Market By Country, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. United States of America (USA) |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Canada |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Competition Landscape |
| 9.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 9.2.1.Varian Medical Systems |
| 9.2.2.Optivus Proton Therapy, Inc. |
| 9.2.3.Mevion Medical Systems |
| 9.2.4.Advanced Oncotherapy plc |
| 9.2.5.ProTom International Inc, |
| 9.2.6.ProNova Solutions LLC |
| 10. Research Methodology |
| 11. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.